Re´actions nucle´aires de spallation induites sur le thorium par des protons de 150 et 82 MeV

Lefórt, M.; Simonoff, G.; Tarrago, X.

doi:10.1016/0029-5582(61)90154-7

Cited by 58 publications

(3 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Proton irradiation of natural thorium ( 232 Th) is another potential avenue for the future of 225 Ac production. Building on early reports, − Zhuikov et al demonstrated a method capable of producing GBq amounts of 225 Ac using high-energy protons (90, 110, and 135 MeV). The dominant production reactions include 232 Th(p,p7n) 225 Th → 225 Ac and 232 Th(p,2p6n) 225 Ac, with the latter contributing 45.8% and 86.5% of produced 225 Ac at 90 and 135 MeV proton energy, respectively .…”

Section: Actiniummentioning

confidence: 99%

Radioactive Main Group and Rare Earth Metals for Imaging and Therapy

2018

View full text Add to dashboard Cite

Radiometals possess an exceptional breadth of decay properties and have been applied to medicine with great success for several decades. The majority of current clinical use involves diagnostic procedures, which use either positron-emission tomography (PET) or single-photon imaging to detect anatomic abnormalities that are difficult to visualize using conventional imaging techniques (e.g., MRI and X-ray). The potential of therapeutic radiometals has more recently been realized and relies on ionizing radiation to induce irreversible DNA damage, resulting in cell death. In both cases, radiopharmaceutical development has been largely geared toward the field of oncology; thus, selective tumor targeting is often essential for efficacious drug use. To this end, the rational design of fourcomponent radiopharmaceuticals has become popularized. This Review introduces fundamental concepts of drug design and applications, with particular emphasis on bifunctional chelators (BFCs), which ensure secure consolidation of the radiometal and targeting vector and are integral for optimal drug performance. Also presented are detailed accounts of production, chelation chemistry, and biological use of selected main group and rare earth radiometals.

show abstract

Section: Actiniummentioning

confidence: 99%

Radioactive Main Group and Rare Earth Metals for Imaging and Therapy

2018

View full text Add to dashboard Cite

show abstract

“…The estimation from MONC for this isotope compared well at low energies of current interest but it overestimates between 50MeV to 100MeV range. Direct production of 229 Th leading to 225 Ac with long half life also has significant cross-section [23] which is very well reproduced by MONC, although it has only single mea- sured data point reported. Direct production of 225 Ac has higher threshold and the measured cross-section [24?…”

Section: Production Of Actiniummentioning

confidence: 79%

“…5, 6, 7, respectively. The cross-section data for 229 Pa are taken from EXFOR data base maintained by IAEA [22,23]. The estimation from MONC for this isotope compared well at low energies of current interest but it overestimates between 50MeV to 100MeV range.…”

Section: Production Of Actiniummentioning

confidence: 93%

Accelerator Based Production of $^{225}$Ac for Cancer Treatment

Kumawat,

Suryanarayana

2020

Preprint

View full text Add to dashboard Cite

Targeted Alpha Therapy potentially offers a more specific action in killing tumor cells and less damage to neighbouring normal cells compared to β-emitters. 225 Ac along with three other αemitting daughter nuclei 221 Fr, 217 At and 213 Po have significant potency for clinical use. Monte carlo simulation has been carried out using MONC code for production routes of 225 Ac for its possible generation using proton accelerators with Thorium-232 and Radium-226 targets. All the calculations has been carried out using global model parameters without adjusting for individual target. The study reveals that proton beam of 20-30MeV energy with 5µA current on radium-226 target can give rise to 1Ci of 225 Ac activity in a week of irradiation. Thorium irradiation at low proton energy produces smaller 225 Ac activity but one can benefit from high current, stable proton accelerators. Proton energy of 100MeV or above with hundreds of µA current can produce reasonable 225 Ac activity for practical use. However, the contamination of other co-produced radioisotopes is much less at low proton energy hence low energy high current proton accelerators are also viable alternative to generate Actinium-225 radio isotope.

show abstract